Batch release testing is one of the most important testing procedures to ensure that drug substances and finished drug products meet established specifications before they are marketed. To minimize the time between production and release, CD Formulation provides validated batch release testing in strict accordance with cGMP regulations to address your protein and peptide physicochemical properties, potency, impurities, identity, purity, and biosafety issues.
Batch release testing is a quality control process that involves testing specific batches or lots of drug substances or finished products to ensure they meet regulatory requirements before being released for distribution or sale. Batch release testing is typically performed to perform analytical assessments of product quality for protein/peptide biopharmaceuticals based on validated compendial (e.g., USP) testing strategies to address product purity, concentration, consistency, identity, and safety.
As an important part of our quality control testing program, protein/peptide batch or lot release testing services are important to ensure the quality control of proteins, monoclonal antibodies (mAbs), or biosimilars.
Fig. 1 Typical GMP batch release testing programs for protein/peptide drug products. (CD Formulation).
With extensive experience and strong expertise in performing biopharmaceutical batch release testing, our team of biopharmaceutical experts regularly develops and validates methods for technology transfer for various analytical methods required for batch release testing.
Our release testing services are applicable to protein therapeutics, peptide therapeutics, protein/peptide biosimilars, monoclonal antibodies, antibody conjugates, and other biologics. We have extensive expertise in all stages of biological product development, from protein chemistry, molecular biology, and cell biology to quality control experience, supporting the entire product development life cycle from early discovery to IND, BLA, etc.
Range | Programs | Analytical Methods |
Physicochemical Properties | Appearance, Color, and Transparency. | Pharmacopoeia |
Osmotic Pressure Testing | Pharmacopoeia | |
pH Testing | pH meter | |
Particle Matter Testing |
|
|
Water Content Testing |
|
|
Identity and Purity | Protein Purity/Concentration |
|
Aggregation |
|
|
Charged variants, Determination of PL | IEF, IE-HPLC. | |
Amino Acid Analysis | De novo sequencing. | |
Glycosylation | Glycan mapping, HPLC. | |
Peptide Mapping | Ultra-high performance liquid chromatography (UV). | |
Protein Variants | RP-HPLC, IEF, IEX, peptide mapping. | |
Primary Structure. |
|
|
Higher Order Structure (HOS) |
|
|
Biological Activity Testing | Potency |
|
Immunogenicity | Anti-drug antibodies (ADAs) and neutralizing antibody NAbs analysis | |
Cellular Bioassay. |
|
|
Microbiological Testing |
|
|
Safety Testing | Process-related Impurities (Host Cell Proteins, HCP). | Ligand Binding Assay (LBA), LC-MS. |
Product-related Impurities | Size exclusion chromatography-high performance liquid chromatography (SEC-HPLC). | |
Extractables and Leachables |
|
Over the past decades, our scientists have accumulated a wealth of valuable experience and successfully generated data for thousands of batches of various protein and peptide products. Our batch release testing expertise includes chemical, physical, and biological testing as well as pharmacopoeial monograph-based testing to support all types of protein/peptide batch release testing listed below.
Published Data
Technology: Multiplex Immunoassay (MIA)
Journal: J Immunol Methods.
IF: 1.6
Published: 2023
Results:
The authors successfully developed a Luminex-based multiplex immunoassay (MIA) method to monitor the consistency of antigen quantity and quality throughout the production process of vaccines produced by different manufacturers. DTaPs from two manufacturers were used for model vaccines. The effectiveness of MIA in vaccine quality control and batch release testing was demonstrated by analyzing over- and under-dosing formulations, heating and H2O2 degradation products, and batch-to-batch consistency of vaccines from two manufacturers.
Fig. 2 Consistency analysis of a panel of batches of different drug products from HuA and HuB obtained by MIA. (Vermeulen M, et al., 2023)
CD Formulation is ready to provide you with batch-release testing services to move your development and manufacturing programs forward. These services adhere to analytical principles of identity, purity, quantity, and product and process-related safety and efficacy. Please feel free to contact us if you are interested in our services or have further questions. We look forward to working with you to promote development and innovation in the biopharmaceutical field.
References